Abstract: Methods are disclosed herein for treating a subject with a lung cancer. The lung cancer can be small cell carcinoma of the lung or non-small cell carcinoma of the lung. The methods include locally administering to the subject a therapeutically effective amount of the polyketal particle comprising a CpG oligodexoynucleotide. Optionally, the polyketal particle can include an imidazoquinoline compound.

Abstract: The invention relates to layered double hydroxide (LDH) materials and in particular to new methods of preparing improved LDH materials which have intercalated active anionic compounds (improved LDH-active anion materials). The improved LDH-active anion materials are characterised by their high degree of robustness, demonstrated by their high Particle Robustness Factor values, and by their ability to retain substantially all of the intercalated active anionic compound, in the absence of ion exchange conditions and/or at pH>4.

Abstract: The present invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides comprising at least one terminal modification.

Abstract: A method for producing an optical imaging contrast agent includes the following process steps: (a) reacting an albumin with a specific organic dye or a salt thereof in an aqueous solution to prepare an aqueous solution containing a combined form of the specific organic dye and the albumin; (b) adjusting the pH of the aqueous solution containing the combined form to 7.2 or less; (c) adding an ester to the aqueous solution having a pH of 7.2 or less and stirring the mixture, thereby preparing a liquid in which an aqueous solution phase and an organic solvent phase containing the ester are separated from each other; and (d) extracting an aqueous solution containing the combined form from the phase-separated liquid.

Abstract: The invention provides compositions for rendering a vitreous cavity visible during a surgical procedure to alleviate a structural disorder caused by the vitreous in an eye, and methods of using the compositions. The compositions are vitreous delineating agents that comprise a hyaluronan binding peptide linked to an optically detectable moiety. Such compositions can be in a formulation that may be a solution, a suspension, or an emulsion, and would be injected into the vitreous shortly prior to use. The composition may additionally contain a therapeutic agent, a diagnostic agent, or a chemosensing material, in use, the composition marks or delineates the vitreous by binding preferentially to the hyaluronan that permeates the vitreous humor and binding little or not at all to surrounding tissues such as the retina.

Abstract: The present invention relates to intraoperative fluorescent imaging (IFI) used both pre-clinically using in-vivo models, as well as clinically to map sentinel lymph nodes in breast cancer, skin cancer, GI cancer, lung cancer, prostate cancer and several other cancers. IFI can be used to image solid tumors both non-specifically in hepatobiliary and breast cancers as well as in prostate and ovarian cancer. In one embodiment, two-dimensional resolution to 10 ?m2 is possible with optical imaging, significantly higher than other imaging modalities. In one embodiment, the present invention relates to a series of self-assembled nanoparticles using HLA (hyaluronic acid) as both a polymeric backbone as well as targeting ligand. In some embodiments, the present invention relates to the synthesis of HLA conjugates, and the effect of variation of the hydrophobic ligand structure and conjugation level on nanoparticle self-assembly, size, ICG loading efficiency, and ICG fluorescence quenching and reactivation.

Abstract: The present invention is directed to improved methods for generating compositions comprising actinium-225.

Abstract: The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

Abstract: The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection.

Abstract: Methods and devices for sterilizing viscous peptide compositions which have shear thinning rheological properties at high concentrations.

Abstract: Systems and methods are provided to reduce noise generated by water and gas discharged after a sterilization treatment, and to prevent adhesion of condensation water on an object to be sterilized. The sterilizer according to the embodiments of the present invention may include a can body having a heater and capable of housing an object to be sterilized; a steam discharge pipe connected to the can body and having an opening and closing means for opening and closing a channel to enable discharging of steam; and a discharged steam tank provided partway along the steam discharge pipe and having a greater channel cross-sectional area than that of the steam discharge pipe.

Abstract: The present disclosure describes a chamber with an interior UV reflective surface, and a light source emitting an ultraviolet light that is used to kill microorganisms on one or more surfaces of an object, thereby sanitizing the object.

Abstract: Systems and methods for creating an oxidation reduction potential (ORP) in water for pathogenic control are described. The systems and methods generate an oxidation reduction potential that provides pathogenic control of the solution as well as pathogenic control of the surfaces with which the solution comes in immediate contact. The system is designed to disinfect and cleanse at least one wall by discharging the water/ozone solution onto the wall at the upper end thereof.

Abstract: The present invention is generally related to a device and method for sanitizing a medical instrument with ozone, in particular the invention relates to a system, method and a device for sanitizing a continuous positive airway pressure (CPAP) device. The device has an ozone compartment, an ozone operating system and one or more ozone distribution lines that distribute ozone to a continuous positive airway pressure device. The device may further include a heater adapter unit to connect heating systems in CPAP devices while distributing ozone to sanitize the CPAP device in accordance with the present invention.

Abstract: A method and apparatus for disinfecting a lavatory inside a vehicle in response to a set of criteria being met. A determination is made as to whether a set of criteria for activation of a disinfection system that emits far-ultraviolet radiation to perform a disinfection process inside a lavatory has been met. In response to a determination that the set of criteria has been met, the disinfection system is activated to perform the disinfection process inside the lavatory using the far-ultraviolet radiation.

Abstract: A malodor control composition having a mixture of volatile aldehydes and methods thereof are provided. The composition is suitable for a variety of applications, including use in fabric and air freshening products.

Abstract: Portable ozone generators and methods of use. For example, a hand-held portable ozone generator has: a housing defining an air inlet, an air outlet, and an air channel communicating between the air inlet and the air outlet; a battery; an ozone generator configured to output, during operation, ozone into the air channel at a non-zero rate that is equal to or below 50 mg/hour; and a controller connected to send control signals to the ozone generator in response to user input. In other cases, a plank or slab shaped portable ozone generator is disclosed, with an air inlet and an air outlet located in respective opposed face plates. In one case the unit has no defined base, and every face and side wall of the device forms a ground engaging base, and the unit functions properly regardless of what face or side wall the unit contacts the ground or a horizontal ground surface with.

Abstract: The present invention relates to a fibrous haemostat composition that is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.

Abstract: The present invention relates to coated silk films. Further, the present invention relates to pharmaceutical or cosmetic compositions comprising the coated silk films. Furthermore, the present invention relates to coated silk films or pharmaceutical compositions comprising the coated silk films for use in medicine. In addition, the present invention relates to methods of producing the coated silk films.

Abstract: Novel semi-crystalline, p-dioxanone-rich ABA triblock copolymers of p-dioxanone and epsilon-caprolactone, where “B” block is a random copolymer of p-dioxanone and epsilon-caprolactone, and absorbable devices for long term medical applications are disclosed. The novel polymer compositions are useful for long term absorbable surgical sutures, and other medical devices.

Abstract: The present invention relates to a fibrous haemostat composition that is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.

Abstract: In one aspect, compositions are described herein. In some embodiments, a composition described herein comprises the reaction product of (i) an alkoxylated or alkenoxylated citric acid, citrate, or ester of citric acid, and optionally a non-alkoxylated and non-alkenoxylated citric acid, citrate, or ester of citric acid, with (ii) a polyol. Additionally, in some cases, a composition described herein comprises the reaction product of (i) and (ii) above and (iii) one or more additional monomers. In some cases, the composition is cross-linked by the use of one or more oxidants such as sodium periodate (NaIO4) and/or silver nitrate (AgNO3), which can be reduced into a reduced oxidant that provides short-term antimicrobial activity. Such a composition can have both short-term and long-term antibiotic and antifungal activity.

Abstract: A hydrogel composition from a cross-linked polymer derived from one or more olefinically unsaturated polymerizable carboxylic monomers and a thermoplastic polyurethane composition is disclosed. The hydrogel exhibits high yield stress at low shear. The hydrogel composition provides useful materials for personal care, health care, medical and pharmaceutical applications, among others.

Abstract: Sliceable bone repair material is a porous block-shaped scaffold containing a hydrogel, wherein the hydrogel is formed by Michael type addition of at least two precursor molecules. Said scaffold is made of a synthetic ceramic material and has interconnected macropores having a diameter above 100 ?m. In addition said scaffold has a total porosity of 80 to 95%. The total volume of the hydrogel is smaller than the total volume of the interconnected macropores.

Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

Abstract: The present disclosure relates to methods and systems for processing isolated mammalian tissue for use in surgical grafting, implantation, or transplantation procedures. The method employs electron beam sterilization, the collagen tissue is partially submerged in rHSA (Recombinant Human Serum Albumin), the tissue is stored in specially designed packaging, and the tissue is stored at ambient temperatures without requiring refrigeration. The terminal sterilization using electronic beams takes place in the special packaging. This inventive technology offers advantages including being biologically safe, maintaining tissue integrity while minimizing size, increasing scalability, increasing shelf life, increasing the amount of tissue usable for transplantation, and reducing of costs associated with processing and storing tissue for long periods of time.

Abstract: Disclosed herein are a cocoon-based, dental barrier membrane for guided bone regeneration and a method for manufacturing the same. The cocoon-based, dental barrier membrane is manufactured by dividing a cocoon into two or more fragments in a predetermined form, the cocoon having a shell having a first thickness. The dental barrier membrane is biocompatible, has excellent tensile strength and porosity, and promotes osteogenesis in a bone defect.

Abstract: The present invention includes compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane powder. The compositions of the present invention comprise amniotic membrane powder and a scaffold. The methods of the present invention comprises applying a composition of the present invention to a subject to induce wound healing and tissue regeneration.

Abstract: An object of the present invention is to provide a composition containing a pancreatic islet, a cell structure containing a pancreatic islet or a pancreatic islet cell, a pancreatic islet transplantation kit, a pancreatic islet transplantation treatment agent, and a hypoglycemic agent which improve at least one of glucose sensitivity or blood sugar level-reducing performance after transplantation, and to provide a composition containing a pancreatic islet, a kit containing a pancreatic islet, a pancreatic islet cell transplantation treatment agent, and a hypoglycemic agent which can improve glucose sensitivity.

Abstract: A bone repair composition including a cancellous bone matrix with cortical and/or cancellous bone particles loaded therein; and a kit comprising the cancellous bone matrix and the cortical and/or cancellous bone particles.

Abstract: This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers.

Abstract: Sliceable bone repair material is a porous block-shaped scaffold containing a hydrogel, wherein the hydrogel is formed by Michael type addition of at least two precursor molecules. Said scaffold is made of a synthetic ceramic material and has interconnected macropores having a diameter above 100 ?m. In addition said scaffold has a total porosity of 60 to 80%. The total volume of the hydrogel is smaller than the total volume of the interconnected macropores.

Abstract: The present invention relates to biomimetic scaffolds, methods for making the same, and methods for using the same. The scaffolds comprise a plurality of graded or tapered microchannels that provide spatial control for cell penetration. The scaffolds are useful for regenerating missing interface tissue between two adjacent tissues, or regeneration and integration of two adjacent tissues directly.

Abstract: This invention discloses a process for preparation of a balloon expandable biodegradable polymer stent with thin struts (strut thickness 130 ?m or less, preferably 100-110 ?m) with high fatigue and radial strength. The invention discloses a process for the preparation of a biodegradable polymer stent which involves radially deforming the biodegradable polymer tube by applying pressure to it with an inert gas at a predefined temperature in multiple stages with each successive stage having a pressure higher than the pressure applied in a previous stage. The process further involves maintaining the predefined temperature and pressure conditions of each stage for a specified time period after application of the pressure.

Abstract: A medical device such as a stent (10) or medical balloon (40) is functionalised prior to coating with a bioactive material (54), specifically by acidification or basification of the contact surface or surfaces (50) of the medical device. Functionalisation with subsequent coating of bioactive agent directly onto the functionalised surface provides a significantly more consistent and reliable coating of bioactive agent on a medical device without requiring containment or time release devices.

Abstract: The invention provides a medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The invention also provides a method of treating a narrowing in a body passageway comprising placing an implantable medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The medicaments can be incorporated within or coated on the device. The invention further provides hydrophobic analogs of medicaments known to inhibit cell proliferation and migration.

Abstract: Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.

Abstract: Systems and methods for providing for the automatic instrument-based rapid reprocessing of an intact extracorporeal circuit for use in hemodialysis. The system includes a manifold with connectors for engaging a dialyzer as well as venous and arterial blood lines. The manifold is adapted to be moved from a dialysis machine to a reuse instrument without removing the dialyzer and associated blood lines. The system allows for reprocessing of the extracorporeal circuit wherein prior to the next treatment, there is no residual chemical disinfectant requiring testing, the extracorporeal circuit is pre-primed, the levels in the bubble traps are set, and all of the required quality assurance tests are performed and recorded.

Abstract: The invention relates to a system for drainage of fluids or wound secretion from body and/or tissue openings of the human or animal body comprising a bag-like reservoir for collecting the fluid or wound secretion, with an upper inlet opening and a lower outlet opening, and a pre-evacuated container with an inlet opening, wherein the inlet opening of the pre-evacuated container is connected to the lower outlet opening of the bag-shaped reservoir.

Abstract: The invention relates to a container for drainage of fluids or wound secretion, comprising an inlet opening to connect with a drainage line and an outlet opening for releasing waste air accumulated inside the container during drainage, which is characterized in that the container is pre-evacuated, and the outlet opening is sealable, so that the container is transferable in a first and in a second operating condition, wherein in the first operating condition the outlet opening is sealed, so that a suction can be achieved at the inlet opening caused by the vacuum inside the container, and in the second operating condition the outlet opening is opened, so that air can enter the container through the outlet opening and neutralize the vacuum present inside the container.

Abstract: The invention relates to a vacuum container for drainage of fluids or wound secretion, wherein the vacuum container is pre-evacuated, with an inlet opening for connection to a drainage line, wherein at the inlet opening a vacuum indicator is located and that the inlet opening is sealable. The invention further relates to a drainage line for drainage of fluids or wound secretion, wherein the drainage line has a vacuum indicator, wherein the vacuum indicator is designed to indicate a vacuum inside a connected vacuum container. Further the invention relates to a system for drainage of fluids or wound secretion, comprising a vacuum container according to the invention and a drainage line.

Abstract: The illustrative embodiments described herein are directed to apparatuses, systems, and methods for managing liquid flow associated with a tissue site that involves using reduced pressure to control fluid flow. In one instance, an apparatus includes a first valve and a second valve in fluid communication with a reduced-pressure source. The valves are movable between an open position and a closed position and are operable to change flow status (open to closed or vice versa) based on a presence of reduced pressure. At least one of the first valve or the second valve is in the closed position to obstruct a flow of a liquid while the other is in the open position. The apparatus also includes a reservoir fluidly coupled to the first valve and the second valve. Other systems, methods, and apparatuses are presented.

Abstract: A device for moving contents of a tube by acting on the exterior of the tube is provided. The device includes a housing having a top portion and a bottom portion, the top portion including a tube passageway extending along a length thereof for holding a tube therein. A roller housed within a roller chassis contacts the tube and is configured to move between a first position in which the tube is disengaged and a second position in which the tube is engaged. A second roller is rotatably coupled to an actuator for rotatably energizing the second roller and is moveable between a first position in which the tube is disengaged and a second position in which the tube is engaged. A lever is operably coupled to the housing and configured to actuate a motor to move the second roller to the second position. The first roller and the second roller are configured to compress the tube to move contents within the tube.

Abstract: A system for treating heart disease, such as pulmonary hypertension or right heart failure, including an implantable component and external components for monitoring the implantable component is provided. The implantable component may include a compliant member, e.g., balloon, coupled to a reservoir via a conduit. Preferably, the compliant member is adapted to be implanted in a pulmonary artery and the reservoir is adapted to be implanted subcutaneously. The external components may include a clinical controller component, monitoring software configured to run a clinician's computer, a patient monitoring device, and a mobile application configured to run on a patient's mobile device.

Abstract: This disclosure relates to making medical solutions. In certain aspects, a method is performed by a data processing apparatus. The method includes introducing liquid into a container that contains a dissolvable solid concentrate in a manner so that a layer of solution above the solid concentrate is maintained at a depth that allows the liquid introduced into the container to agitate the solution adjacent to the solid concentrate to cause mixing of the solid concentrate with the solution.

Abstract: A system that fills multiple containers includes a filter with an inlet port and multiple outlet ports. The outlet ports are pre-attached to containers by respective filling lines of each container. Each container has an interior and each of the respective filling lines is connected to a respective container interior. All of the respective filling lines are sealed to the outlet ports and the containers such that the container interiors are isolated from an external environment except the inlet port, via the filter, forming a combined interior volume which is sterile. The system can produce batches of multiple sterile containers with sterile medicament in the containers.

Abstract: This disclosure relates to medical fluid cassettes and related systems and methods. In certain aspects, a medical fluid cassette includes a base having a first region and a second region, a first membrane overlying the first region of the base, and a second membrane overlying the second region of the base. The second membrane is configured to rebound away from the base when a force used to press the second membrane toward the base is released.

Abstract: A method of performing a peritoneal dialysis treatment includes connecting a disposable unit to a source of water. The disposable unit includes at least a first container holding a sterile concentrate containing an osmotic agent, a second container holding a sterile concentrate containing electrolytes, an empty sterile mixing container, and a tubing set with a pre-attached peritoneal fill/drain line. The method also includes receiving a prescription command by a controller, indicating at least the fill volume and desired final concentration of the osmotic agent to be used for a current fill cycle under said treatment, and pumping a quantity of the concentrated osmotic agent that is at least sufficient to achieve the desired final concentration into the mixing container. The contest of the mixing container are mixed, further diluted or concentrated, and then flowed to a patient.

Abstract: A disposable fluid circuit used in a medical device that performs peritoneal dialysis includes a peritoneal dialysis tubing set that has a connection tube with a connector for a peritoneal catheter at a distal end and a connector configured to connect to a peritoneal cycler at a proximal end. The circuit also includes a pressure pod at the distal end, the pressure pod being of the type that has a flow chamber for carrying a liquid and an air chamber separated from the flow chamber by a diaphragm and an air port in fluid communication with the air chamber. The flow chamber is connected in-line with a lumen of the connection tube and a length of tubing runs from the air-port along the length of the connection tube with a connector at the proximal end configured to connect to a pressure transducer.

Abstract: A method of performing a dialysis treatment includes using a pump and a dialysate supply line to transport peritoneal dialysis fluid, the supply line having a proximal end into which peritoneal dialysis fluid is supplied and from which spend dialysate is withdrawn, and a distal end which is connected to a patient's peritoneal access. The method further includes generating proximal and distal pressure signals using pressure detectors located at both the proximal and distal ends, respectively, of said supply line. During a drain cycle in which spent dialysate is pumped from the patient, the method includes, responsively to the proximal and distal pressure signals, detecting a characteristic of a pressure difference between the distal and proximal ends whose magnitude is determined by a predicted change in dialysate properties, and responsively to the characteristic, generating a signal indicating the change in dialysate properties.